Awakn Life Sciences Corp.


Change: Change(%):
Volume: Open:
High: Low:
52Wk High: 52Wk Low:

Company News 

9/15/2022 – Awakn Life Sciences Reports Strong Q2 2022 Results

9/12/2022 – Awakn Life Sciences Signs Drug Development Agreement with Catalent for Zydis(R) Technology (An Orally Disintegrating Tablet) to Conduct Feasibility Studies to Improve Differentiation of Its MDMA Program

8/25/2022 – Awakn Life Sciences Signs Agreement with a Leading Drug Development Company to Deepen IP Moat for Its Lead Program

8/18/2022 – Awakn Life Sciences Signs Second Licensing Partnership Agreement and Expands Commercial Operations Into Canada

8/15/2022 – Awakn Life Sciences Expands Commercial Operations into the U.S. - First Licensing Partnership Agreement with Revitalist

8/15/2022 –  Revitalist Partners with Awakn Life Sciences as First Licensee in the United States to begin Redefining Treatment for Addiction, Recovery, and Relapse Prevention in the Psychedelic Space

7/20/2022 – Awakn Life Sciences' Phase III Trial Approved for Approximately CA$2.5 Million Funding from UK State Covering 66% of Costs

7/15/2022 – Awakn Life Sciences Provides a Business and Corporate Update

7/5/2022 – Awakn Life Sciences Receives UK State Funding to Identify Optimal Pathway to Market in UK & US for Its Lead Clinical Development Program - Ketamine-Assisted Therapy for Alcohol Use Disorder